Asio Capital LLC Makes New $3.42 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Asio Capital LLC opened a new position in Regeneron during the fourth quarter, buying 4,434 shares valued at approximately $3.42 million.
• Insiders sold 3,774 shares worth about $2.94 million in the last 90 days, including Director Huda Y. Zoghbi (1,638 shares at $781.33) and SVP Jason Pitofsky (2,036 shares at $778.52), leaving insiders with 7.02% ownership.
• Fundamentals and sentiment: Regeneron beat Q4 EPS estimates ($11.44 vs. $10.74), raised its quarterly dividend to $0.94 (annualized $3.76, yield ~0.5%), has a market cap of about $80.4 billion, and holds a consensus analyst rating of "Moderate Buy" with a $804.70 price target.

Asio Capital LLC acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 4,434 shares of the biopharmaceutical company's stock, valued at approximately $3,422,000.

Other large investors also recently added to or reduced their stakes in the company. Board of the Pension Protection Fund purchased a new position in Regeneron Pharmaceuticals during the fourth quarter worth $31,000. Salomon & Ludwin LLC purchased a new position in Regeneron Pharmaceuticals during the third quarter worth $27,000. FNY Investment Advisers LLC purchased a new position in Regeneron Pharmaceuticals during the fourth quarter worth $38,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in Regeneron Pharmaceuticals during the second quarter worth $31,000. Finally, Caitlin John LLC purchased a new position in Regeneron Pharmaceuticals during the third quarter worth $34,000. 83.31% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, Director Huda Y. Zoghbi sold 1,638 shares of the business's stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $781.33, for a total value of $1,279,818.54. Following the completion of the sale, the director owned 1,703 shares in the company, valued at approximately $1,330,604.99. The trade was a 49.03% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Jason Pitofsky sold 2,036 shares of the business's stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the completion of the sale, the senior vice president owned 4,272 shares of the company's stock, valued at approximately $3,325,837.44. This represents a 32.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 3,774 shares of company stock worth $2,942,738. 7.02% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock opened at $760.27 on Wednesday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $821.11. The stock has a market capitalization of $80.38 billion, a price-to-earnings ratio of 18.29, a P/E/G ratio of 2.02 and a beta of 0.40. The stock has a fifty day simple moving average of $766.41 and a two-hundred day simple moving average of $717.18. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, topping the consensus estimate of $10.74 by $0.70. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The business had revenue of $3.88 billion during the quarter, compared to analysts' expectations of $3.76 billion. During the same period in the prior year, the business earned $12.07 EPS. The business's revenue for the quarter was up 2.5% compared to the same quarter last year. On average, analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 5th. Shareholders of record on Friday, February 20th were issued a $0.94 dividend. The ex-dividend date was Friday, February 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. This is a positive change from Regeneron Pharmaceuticals's previous quarterly dividend of $0.88. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 9.05%.

Wall Street Analysts Forecast Growth

REGN has been the subject of several analyst reports. Morgan Stanley raised their price objective on shares of Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the stock an "equal weight" rating in a research note on Monday, February 2nd. Cantor Fitzgerald increased their target price on Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the stock an "overweight" rating in a research note on Monday, February 2nd. Oppenheimer reiterated an "outperform" rating and issued a $865.00 target price (up from $750.00) on shares of Regeneron Pharmaceuticals in a research note on Monday, February 2nd. Weiss Ratings reiterated a "hold (c)" rating on shares of Regeneron Pharmaceuticals in a research note on Friday, March 27th. Finally, Bank of America upgraded Regeneron Pharmaceuticals from an "underperform" rating to a "buy" rating and increased their target price for the stock from $627.00 to $860.00 in a research note on Wednesday, January 7th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $804.70.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.